Assignee
HIBERCELL INC
US·10 granted patents·17 pending applications·3 citations·filing 2013–2024
Top patents by PatentIndex Score
27 records- 0182US2025009782A1Beta-glucan immunotherapies affecting the immune microenvironmentHIBERCELL INC·Filed 2024·Application pending·0 cites
- 0281US2025114392A1Beta-glucan in combination with anti-cancer agents affecting the tumor micrenvironmentHIBERCELL INC·Filed 2024·Application pending·0 cites
- 0380US11229701B2Methods for identifying beta-glucan binding to immune cellsHIBERCELL INC·Filed 2013·Granted Jan 25, 2022·2 cites·6 claims
- 0480US2024350528A1Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironmentHIBERCELL INC·Filed 2023·Application pending·0 cites
- 0579US2025114391A1Beta-glucan methods and compositions that affect the tumor microenvironmentHIBERCELL INC·Filed 2024·Application pending·0 cites
- 0678US11667651B2Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitorsHIBERCELL INC·Filed 2018·Granted Jun 6, 2023·1 cites·11 claims
- 0776US12390526B2Methods for identifying beta-glucan binding to immune cellsHIBERCELL INC·Filed 2021·Granted Aug 19, 2025·0 cites·9 claims
- 0874US2023172967A1Beta-glucan immunotherapies affecting the immune microenvironmentHIBERCELL INC·Filed 2022·Application pending·0 cites
- 0973US2022117998A1Beta-glucan immunotherapies affecting the immune microenvironmentHIBERCELL INC·Filed 2021·Application pending·0 cites
- 1070US12006332B2Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitorsHIBERCELL INC·Filed 2022·Granted Jun 11, 2024·0 cites·15 claims
- 1170US2024158415A1Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitorsHIBERCELL INC·Filed 2023·Application pending·0 cites
- 1268US2022047620A1Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironmentHIBERCELL INC·Filed 2021·Application pending·0 cites
- 1367US2024019444A1Beta glucan immunopharmacodynamicsHIBERCELL INC·Filed 2023·Application pending·0 cites
- 1467US2021283169A1Beta-glucan methods and compositions that affect the tumor microenvironmentHIBERCELL INC·Filed 2021·Application pending·0 cites
- 1560US2025339426A1Gcn2 modulator for treating cancerHIBERCELL INC·Filed 2023·Application pending·0 cites
- 1654US11498929B2Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitorsHIBERCELL INC·Filed 2020·Granted Nov 15, 2022·0 cites·13 claims
- 1753US12473296B2Perk inhibiting compoundsHIBERCELL INC·Filed 2020·Granted Nov 18, 2025·0 cites·28 claims
- 1852US11815435B2Beta glucan immunopharmacodynamicsHIBERCELL INC·Filed 2018·Granted Nov 14, 2023·0 cites·7 claims
- 1952US2024150345A1Gcn2 modulating compounds and uses thereofHIBERCELL INC·Filed 2022·Application pending·0 cites
- 2052US2022348584A1Perk inhibiting indolinyl compoundsHIBERCELL INC·Filed 2020·Application pending·0 cites
- 2151US2022356186A1Perk inhibiting pyrrolopyrimidine compoundsHIBERCELL INC·Filed 2020·Application pending·0 cites
- 2251US2024083897A1Gcn2 modulating compounds and uses thereofHIBERCELL INC·Filed 2022·Application pending·0 cites
- 2347US2022388964A1(aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditionsHIBERCELL INC·Filed 2020·Application pending·0 cites
- 2445US12331054B2Perk inhibiting imidazolopyrazine compoundsHIBERCELL INC·Filed 2020·Granted Jun 17, 2025·0 cites·36 claims
- 2543US11584763B2Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitorsHIBERCELL INC·Filed 2018·Granted Feb 21, 2023·0 cites·16 claims
- 2642US2021283168A1Beta glucan and cd40 agonist combination immunotherapyHIBERCELL INC·Filed 2019·Application pending·0 cites
- 2740US11919902B2Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitorsHIBERCELL INC·Filed 2018·Granted Mar 5, 2024·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when HIBERCELL INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →